News und Analysen
Poxel Announces its Participation at Upcoming Scientific Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
Vistagen Announces Pricing of $100 Million Underwritten Offering
Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression
Novocure to Report Third Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will
EQS-News: Abivax files registration statement for proposed initial public offering in the United States
EQS-News: Abivax announces the release of its 2023 half-year financial report
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-News: Eckert & Ziegler Receives Award for Professional Training
OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1
Xencor to Present Multiple Posters at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three
Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alisertib, a selective
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine
EQS-News: Abivax presents first-half 2023 financial results
PINC AI™ and Fortune Name the Nation’s 100 Top Hospitals®
PINC AI™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 100 top hospitals. The full list of recognized hospitals was published in an exclusive
Simulations Plus Receives New FDA Grant Award
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced it has